trending Market Intelligence /marketintelligence/en/news-insights/trending/cy6nyfucm6m5hb3hziwpaq2 content esgSubNav
In This List

Innate Immunotherapeutics appoints chairman

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Innate Immunotherapeutics appoints chairman

Sydney's Innate Immunotherapeutics Ltd. appointed Warwick Tong to the position of chairman.

Tong joined the biotechnology company's board on May 4, after it acquired Amplia Therapeutics Pty Ltd.

Tong's previous roles include CEO of Cancer Therapeutics Cooperative Research Centre and senior positions at GlaxoSmithKline PLC.

Innate Immunotherapeutics develops, makes and sells drugs in Australia and New Zealand.